全文获取类型
收费全文 | 1266398篇 |
免费 | 97170篇 |
国内免费 | 1588篇 |
专业分类
耳鼻咽喉 | 16589篇 |
儿科学 | 41211篇 |
妇产科学 | 35118篇 |
基础医学 | 189413篇 |
口腔科学 | 35046篇 |
临床医学 | 118090篇 |
内科学 | 247691篇 |
皮肤病学 | 27564篇 |
神经病学 | 102073篇 |
特种医学 | 47552篇 |
外国民族医学 | 272篇 |
外科学 | 179995篇 |
综合类 | 25788篇 |
现状与发展 | 3篇 |
一般理论 | 570篇 |
预防医学 | 104672篇 |
眼科学 | 28217篇 |
药学 | 93045篇 |
6篇 | |
中国医学 | 1971篇 |
肿瘤学 | 70270篇 |
出版年
2018年 | 13739篇 |
2017年 | 10564篇 |
2016年 | 11570篇 |
2015年 | 13321篇 |
2014年 | 18296篇 |
2013年 | 27835篇 |
2012年 | 38155篇 |
2011年 | 40588篇 |
2010年 | 23396篇 |
2009年 | 22601篇 |
2008年 | 38339篇 |
2007年 | 40965篇 |
2006年 | 40557篇 |
2005年 | 39703篇 |
2004年 | 38118篇 |
2003年 | 36411篇 |
2002年 | 35308篇 |
2001年 | 56373篇 |
2000年 | 57329篇 |
1999年 | 48110篇 |
1998年 | 12603篇 |
1997年 | 11438篇 |
1996年 | 11822篇 |
1995年 | 11923篇 |
1994年 | 11131篇 |
1993年 | 10411篇 |
1992年 | 38384篇 |
1991年 | 37892篇 |
1990年 | 36676篇 |
1989年 | 35469篇 |
1988年 | 32854篇 |
1987年 | 32194篇 |
1986年 | 30682篇 |
1985年 | 28941篇 |
1984年 | 22063篇 |
1983年 | 19248篇 |
1982年 | 11390篇 |
1981年 | 10336篇 |
1979年 | 20996篇 |
1978年 | 15436篇 |
1977年 | 12790篇 |
1976年 | 11847篇 |
1975年 | 12855篇 |
1974年 | 15645篇 |
1973年 | 15404篇 |
1972年 | 14569篇 |
1971年 | 13615篇 |
1970年 | 12832篇 |
1969年 | 12128篇 |
1968年 | 11257篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
12.
13.
14.
15.
16.
17.
18.
19.
Raymond E. Chen Emma Knapp Bowen Qiu Anthony Miniaci Hani A. Awad Ilya Voloshin 《Seminars in Arthroplasty》2022,32(1):145-153
BackgroundThe purpose of this study was to compare initial fixation strength between various stemless and stemmed humeral components and to correlate implant fixation strength with bone mineral density (BMD).MethodsFive humeral stem designs were investigated: Stemless-A (four hollow fins), Stemless-B (central body, three solid fins), Stemless-C (central screw, peripheral rim-fit), Short stem (50 mm), and Standard stem (130 mm). Fifty cadaveric human humerii were obtained and divided into five groups. BMD within the humeral head was determined for all samples. The mean BMD was similar between groups. The 25 samples with the lowest and highest BMDs were categorized as “Low” and “High,” respectively, with a BMD threshold of 0.35 g/cm2, creating BMD subgroups. After implantation, each sample underwent a standardized biomechanical testing protocol, with axial loading followed by torsional loading. Sensors attached to the specimen recorded micromotion throughout testing. Axial loading consisted of cyclic loading for 100 cycles at 3 peak forces (220, 520, and 820 N). Torsional loading consisted of 100 cycles of internal/external rotation at 0.1 Hz at 6 peak torques, or until failure (±2.5, 5, 7.5, 10, 12.5, and 15 Nm). Failure was defined as the torque at which any bone fracture, implant detachment from anchor/stem, or an excess of 50° internal/external rotation occurred. Groups and BMD subgroups were compared.ResultsAt maximal axial loading, Stemless-B demonstrated greater micromotion (540 μm) than Stemless-C (192 μm) (P = .003). Stemless-B and Stemless-A (387 μm) also had greater micromotion than Short stem (118 μm, P < .001, P = .03) and Standard stem (85 μm, P < .001, P = .01). When comparing low-BMD samples at maximal axial loading, these differences were accentuated, but comparison of high-BMD samples showed no significant differences between groups. Torsional testing demonstrated that Standard stem failed at greater torque (7.2 Nm) than Stemless-B (2.3 Nm, P < .001), Stemless-A (1.9 Nm, P < .001), and Stemless-C (3.9 Nm, P = .01). When comparing torsional testing results of low-BMD samples, both Standard stem and Short stem failed at greater torque than Stemless-B (P = .02, P = .003) and Stemless-A (P = .03, P = .004) but failed at a similar torque to Stemless-C. Torsional testing of high-BMD samples showed that Standard stem failed at a greater torque than all stemless designs.ConclusionStemless humeral implants should be used with caution in low-BMD settings (<0.35 g/cm2). A central screw and peripheral rim-fit stemless anchor design demonstrated greater fixation strength at low BMD when compared with other designs, while all stemless designs performed similarly at high BMD.Level of evidenceBasic Science Study; Cadaveric Study 相似文献
20.
Janitz Amanda E. Schraw Jeremy M. Xu Chao Lupo Philip J. 《Cancer causes & control : CCC》2022,33(3):483-488
Cancer Causes & Control - Congenital malformations are strong risk factors for childhood cancer. Our objective was to determine whether cancer survival differs by birth defect status among... 相似文献